MMP9 and colorectal carcinoma: A study using 17-AAG (also named as Tanespimycin) with capecitabine (Cap) or irinotecan (IR) demonstrated a marked downregulation of MMP9 and VEGF in CRC cells, particularly in HT-29 cells.